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Background and objectives: Male infertility is a global health dilemma and
Follicle-Stimulating Hormone (FSH) administration has shown promising results. Several
studies showed that infertile men with normal semen parameters have low levels
of DNA damage while infertile men with abnormal semen parameters have more
damage at the DNA level. Sperm DNA damage may affect the reproductive outcome
and has been associated with failure in the achievement of competent embryos and
pregnancy fulfillment. The aim of this study was to evaluate whether the administration
of recombinant FSH (Gonal-f® PEN 900 IU) could improve sperm DNA fragmentation
in men with infertility. The secondary endpoints of this study were to evaluate the FSH
effects on sperm parameters and hormonal assets.
Methods: A longitudinal, prospective, multicenter, open-label clinical trial was carried
out. Infertile couples were recruited from six Italian Reproductive Medical Centers
and 115 infertile men were enrolled for this study. All participants were treated with
subcutaneous injections of Gonal-f® 150 IU every other day, within a 3 month-time
frame. The semen samples were examined in accordance to the 2010 World Health
Organization criteria. Sperm DNA Fragmentation (DFI) was determined by fluorescence
microscopy using terminal deoxynucleotidyl transferase-mediated d-UTP Nick-end
Labeling (TUNEL) assay. Statistical analysis was performed using both the t-test for
paired samples and the Wilcoxon signed-rank test.
Results: FSH administration improved DFI in 67% of patients, with an average decrease
of 35.4% compared to the baseline. This improvement is more evident in men with basal
DFI lower than 17% and in those with FSH basal levels between 2.16 and 4.27 IU/L. In
addition, FSH enhanced the gonadal function, increasing the hormones AMH and Inhibin
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B and semen parameters. Limitation of these results are represented by the absence of
a placebo group and of FSHR genotype stratification sub-analysis.
Conclusion: Recombinant FSH 150 IU is well tolerated and effective in eliciting a
significant DFI reduction as well as in improving gonadal function.
Trial Registration: EUDRACT Number 2010-020196-23. Registred 14 April 2011.
Keywords: male infertility, sperm DNA fragmentation, DNA fragmentation index, functional hypogonadotropic
hypogonadism, recombinant FSH
INTRODUCTION
Male unexplained infertility defines those cases in which men are
infertile despite having normal semen analysis, normal history
and physical examination and when female factor infertility
has been ruled out (1). Male infertility, a current global health
dilemma, affects approximately 10–15% of male adults and up to
one in six couples, and in 30–40% of cases, a definite cause for
infertility cannot be found (2, 3). In this context, abnormalities in
the spermDNA integrity should be researched and several studies
showed that infertile men with normal semen parameters have
low levels of DNA damage while, infertile men with abnormal
semen parameters have more damage at the DNA level (4).
Moreover, up to 8% of infertile men showed an altered DNA
integrity together with normal semen parameters (5).
The role of Follicle-Stimulating Hormone (FSH) on
spermatogenesis is widely demonstrated both in animals (6) and
in humans (7, 8). As a confirmation of this, the use of FSH 150
IU in combination with human Chorionic Gonadotropin (hCG)
3 times a week for up to 18 months, is effective at initiating
spermatogenesis in the vast majority of cases of azoospermia
due to Hypogonadotropic Hypogonadism (HH) (9). Starting
from this point, the administration of FSH has been proposed
in cases of oligoasthenoteratozoospermia with low-normal
FSH serum levels, using the same FSH doses proposed in the
HH. These cases represent a functional HH and the hormonal
pattern of these patients suggests that gonadotropins are not
able to maintain normal spermatogenesis, although they are in
the low-normal range (9). Thus, these infertile patients could
benefit from a gonadotropin-based treatment. While in other
countries FSH is not approved for male infertility treatment,
in Italy, the note number 74 of the Italian Medicines Agency
(AIFA) approves the use of FSH in infertile men who want to
conceive with “Hypogonadotropic Hypogonadism and normal
or low gonadotropin levels, with FSH < 8 IU/L” (10). Several
clinical trials, evaluated the effectiveness of the recombinant FSH
treatment in improving the sperm quality in male subjects with
idiopathic infertility, although no clear, distinct results have been
obtained as of yet (11). A recent meta-analysis confirmed that
an average of 12 week of FSH treatment improves the pregnancy
Abbreviations: AE, Adverse Event; AIFA, Italian Medicines Agency; AMH,
Anti-mullerian hormone; DFI, DNA Fragmentation Index; FSH, Follicle-
Stimulating Hormone; hCG, Chorionic Gonadotropin; HH, Hypogonadotropic
Hypogonadism; ICSI, Intracytoplasmic Sperm Injection; LH, Luteinizing
Hormone; SHBG, Sex Hormone Binding Globulin; TUNEL Assay, Terminal
Deoxynucleotidyl Transferase-Mediated d-UTP Nick-end Labeling Assay.
rate, both in natural cycles and after assisted reproductive
techniques, independently from the FSH preparation used
(recombinant/purified), but without any clear correlation with
duration of FSH administration or cumulative dose. Also, the
Authors stated that FSH administration showed significant
benefits on sperm concentration, but not on sperm progressive
motility (11). Moreover, Simoni et al. recently confirmed the
efficacy of FSH in men with idiopathic infertility, performing
a multicenter, longitudinal, prospective, open-label, two-arm
clinical trial in which the sperm DNA Fragmentation Index
(DFI) was used as a primary endpoint (12). However, adequately
driven clinical trials are still needed to strengthen the knowledge
of the FSH efficacy in this setting.
Semen analysis remains the main tool used in the clinical
practice to evaluate male fertility. The sperm parameters
evaluated are: volume, sperm concentration, total sperm number,
motility and morphology (13). However, seminal parameter
values, concerning fertile and infertile men, have a wide
overlap, and increasingly stringent parameters should be used
to evaluate the male reproductive capability before and after
a pharmacological therapy (14). DFI has recently drawn the
attention in the research field of human reproduction. Although
there is evidence of successful Intracytoplasmic Sperm Injection
(ICSI) cycles, it has been shown that such parameters might
negatively affect the reproductive outcome, both in natural cycles
and in assisted reproduction settings (14, 15). Sperm DNA
damage has been associated with failures in the achievement of
competent embryos and pregnancy fulfillment (15), and the DFI
represents the best tool to evaluate sperm DNA damage (16).
The aim of this clinical study (EUDRACT Number 2010-
020196-23) was to evaluate the effects of the recombinant FSH
administration, 150 IU every other day in a 3-month time frame,
on sperm DNA damage evaluated through DFI in male partners
of infertile couples with low-normal FSH levels. The secondary
endpoints of this study were to evaluate the FSH effects on sperm
parameters and hormonal assets.
MATERIALS AND METHODS
Study Design
A longitudinal, prospective, interventional, open-label, clinical
trial was carried out. Three visits were carried out, performed
at baseline (Visit 0), at 1 month (Visit 1) and at 4 months (Visit
2) from baseline. During Visit 0, infertile couples were evaluated
and the male partner was checked for inclusion and exclusion
criteria. Visit 1 coincided with the FSH treatment start, and it was
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performed within 30 days from the baseline, in accordance to the
clinician’s judgement. The treatment phase lasted 3 months and
ended at Visit 2. The maximum study duration per patient was 4
months. The study design is summarized in Figure 1.
During the baseline visit, the Endocrinologist at each Center
evaluated the patients concerning the anamnesis, the physical
examination and the testicular ultrasound. Semen and blood
samples were obtained at Visits 0 and 2 to evaluate the pre- and
post-treatment effects of the FSH administration (at Visits 0 and
2, respectively). The semen and the blood samples were sent to
the Central Laboratory within 3 days after being collected.
Patients
The protocols and the patient informed consents were reviewed
and approved by the local Ethics Committees (ECs) of the
involved recruiting sites. The Ethics Committee of the II
University of Naples released the EC approval of the National
Coordinating Site. The study origin and conduct were in
accordance with the Declaration of Helsinki as amended by the
59thWMAGeneral Assembly, Seoul, Republic of Korea, October
2008, and compliant with the GCP guidelines and relevant Italian
regulation.
Recruitment took place at six Italian Reproductive Medicine
Centers in which the male partner of the selected infertile
couple was thoroughly evaluated (Rome, Naples, Siena, Palermo,
Milan, Bari), through a competitive recruitment model. The first
patient was enrolled on July 8th 2011. The last study visit was
performed on February 28th 2013. Patient informed consent for
the pre-screening procedures was obtained prior to the eligibility
assessment.
In the enrolment phase, the infertile couples (no pregnancies
after at least 12 months of unprotected intercourse) in which
the male partner presented the following inclusion criteria,
were considered: (i) age between 18 and 45 years, (ii) total
sperm number of >10 million/ejaculate, (iii) total sperm
motility of >5% and ≤25%, and (iv) FSH value at baseline
>1 and <8 IU/L. Although not strictly related to the male
infertility definition (13), these parameters were chosen, taking
into consideration the FSH rules provided by the AIFA
note number 74 of the FSH together with the minimum
number of sperm required for the chromatin integrity analysis.
Thus, patients with both unexplained infertility and idiopathic
infertility were included. Moreover, during the first visit,
obvious female infertility causes have been excluded through the
anamnesis.
FIGURE 1 | Study design.
Each patient was evaluated at the enrolling Center and
the following conditions were evaluated in accordance to
their clinical practice as exclusion criteria: HH, history of
testis trauma, torsion, or prior vasectomy reversal, documented
presence of urogenital tract infections, any clinically important
systemic disease, any diagnosed or suspectedmalignant androgen
dependent tumors, genetic disorders; documented presence of
varicocele by physical examination and confirmed by ultrasound
(III degree or higher at the ultrasound evaluation) (17),
documented presence of hydrocele, and no medical or surgical
treatment in the 3 months prior to the study. Moreover,
patients with known genetic causes of male infertility (karyotype
abnormalities, and CFTR gene mutations, etc.) have been
excluded. Smoking behavior represented a criterion for exclusion
only when a current attitude to 20 or more cigarettes/day was
discovered or a former attitude of 41 or more cigarettes/day
with discontinuation within 6 months before the screening visit.
Considering exclusion criteria, smokers were included in the
study, only when the attitude was less than 20 cigarettes per day.
Treatment
All enrolled patients received the recombinant FSH (Gonal-f R©
Pen) treatment, subcutaneously administered, at a 150 IU dosage
every other day, starting from Visit 1, for a total period of 3
months. An authorized and trained member of the research
staff administered the first injection at the designated research
center. The subsequent administrations were performed in other
medical facilities or at home, as found suitable for each case.
In case of self-administration, the research center instructed
the patient on the injection protocol to be carried out. The
investigator advised the patient on the injection sites to be
chosen. The site staff ensured that the self-administering patients
properly followed the protocol.
The Sponsor of the trial, Merck Serono, supplied study
medication for this protocol. The Gonal-f R© Pen 900 IU is
a disposable, pre-filled drug delivery system intended for
subcutaneous injection of multiple and variable doses of liquid
formulation of follitropin alfa. The product was to be stored
in a refrigerator (2–8◦C), never under frozen conditions, and
protected from direct light source. Before opening and within
its shelf-life, the medicinal product could be removed from
the refrigerator, without being refrigerated again, for up to 3
months at/or below 25◦C temperatures. The product had to be
discarded if it had not been used after 3 months. Once opened,
the medicinal product could be stored for a maximum of 28 days
at/or below 25◦C temperatures. The investigator had to write on
the Gonal-f pre-filled pen, the day of its first use. Each study kit,
which was dispensed to the participants, was made up of 8 (eight)
Gonal-f R© pre-filled devices.
Laboratory Analysis
Blood analyses were performed at the Core Laboratory of
Seminology (Department of Experimental Medicine University
of Rome “La Sapienza,” Italy). The hormone parameters were
evaluated in a peripheral blood sample collected in the morning
(7:30–9:00 a.m.), after fasting overnight. The samples were
centrifuged after 30’ and the serum was immediately frozen
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at −20◦C temperature. All tests were performed in duplicate.
FSH, LuteinizingHormone (LH), testosterone, and SexHormone
Binding Globulin (SHBG) were measured by Chemiluminescent
Micro-particle Immunoassay (CMIA, Architect System) (Abbott
Laboratories, IL, USA), with limits of detection set at 0.05 IU/L,
0.07 IU/L, 0.0144 ng/ml and 0.1 nmol/L, respectively. The normal
adult ranges for our laboratory are FSH 1.38–9.58 IU/L, LH
1.80–8.16 IU/L, testosterone 2.8–11.0 ng/ml, SHBG 11.7–78.1
nmol/L. The Inhibin B serum and the AMH were measured
by an enzymatic immunoassay (ELISA, Pantec-Italy). The limit
of detection was set at 7.0 pg/mL and 0.14 ng/mL respectively.
The Inhibin B normal post-pubertal range for our laboratory is
80–380 pg/mL.
Semen Analysis
The semen samples were collected by means of masturbation
directly into a sterile plastic container after a 2–7 day period
of sexual abstinence, according to WHO 2010. This criteria
was strictly observed because of the possible influence on the
study outcome (18). They were examined in accordance to the
2010 World Health Organization criteria (13) and the following
variables were taken into consideration: sperm concentration (n
×106/ml), total sperm number (n ×106/ejac.), total motility (%)
and morphology (% abnormal forms).
One aliquot of each of the raw semen samples was treated for
sperm DNA integrity.
DNA Fragmentation
The DFI was determined by fluorescence microscopy using
terminal deoxynucleotidyl Transferase-mediated d-UTP Nick-
end Labeling (TUNEL) assay (In situ Cell Death Detection Kit,
Fluorescein; Roche, Basel, Switzerland) following the procedure
described by Gandini et al. (4). One aliquot of each of the
raw semen samples was washed twice with NaCl 0.9% solution,
the pellets resuspended in PBS containing 10% glycerol to a
final sperm concentration of 10 × 106/mL and transferred to
Eppendorf snap-cap tubes. The tubes were stored at −80◦C.
After thawing samples were then cytocentrifuged for 5min at
200 g and then incubated with a solution of 0.1% Triton X-
100 (Sigma, St Louis, MO, USA; T-8787) and 0.1% Sodium
Citrate (Sigma, C-8532) for 2min on ice. After two washing
cycles, the slides were air dried and 30 µl of TUNEL mixture
(terminal deoxynucleotidyl Transferase and fluorescein-dUTP)
were added to each sample. Slides were covered with 22x22mm
coverslips. Samples were incubated 60min in a moist chamber
in the dark, washed three times with PBS and then analyzed
under fluorescence microscope (Leica DMR; Leica, Wetzlar,
Germany), counting at least 500 cells. The analyses were centrally
performed at the Core Laboratory of Seminology (Department
of Experimental Medicine University of Rome “La Sapienza”,
Italy).
Statistical Analysis
The sample size of the study was calculated by considering
a difference between the baseline and the final DFI equal or
greater than two percentage points, with a Standard Deviation
(SD) of 6.5. The calculation was performed assuming a normal
distribution of DFI, using a two sided t-test, with a statistical
power of 90% and α-error = 0.05. The sample size calculation
indicated that 113 would be a suitable number of patients to enrol
in the study.
The population normality was verified by using the
Kolmogorov-Smirnoff and Shapiro-Wilk tests. Differences
between the DFI, before and after treatment, have been verified
by the t-test for paired samples or the Wilcoxon signed-rank
test, depending on the distribution of the DFI changes. The
statistical analysis of the hormonal parameters was performed
using both the t-test for paired samples and the Wilcoxon
signed-rank test. The efficacy endpoints were considered as
present or absent for the main analysis. For the definition of
efficacy, the null hypothesis was that no change in the DFI
occurred after treatment, therefore, this statistically significant
result was expected if a difference of at least two percentage
points between baseline and Visit 2 was detected. Univariate
analysis was performed to verify the null hypothesis. In order
to compare the results for the DFI pre- and post-treatment
parameters, the relative efficacy for the DFI parameter X as (Xt –
X0)/X0, where X0 is the pre-treatment value and Xt is the value of
the DFI parameter post treatment were subsequently calculated.
The linear regression analysis was performed considering the
DFI as a dependent variable.
Statistical analysis was performed with the SPSS R© software
(version 17 and version 20). Confidence intervals at 95%
were computed and statistical tests were performed at a 5%
significance level.
RESULTS
One hundred and twenty-five eligible couples were screened and
115 men were enrolled in accordance to the inclusion and the
exclusion criteria. During the treatment phase, four drop-outs
were recorded and a total of 111 patients completed the study
(Figure 2). The power of the analysis performed, was 89.7%. Six
adverse events were recorded during the study, although none of
these was life threating and in all cases it was a transitory event.
The average age of the participants was 36.09 ± 4.67 years old
(range 24–46 years). The sperm DNA fragmentation of 8 patients
was not assessable due to the unsuitability of the collected sample.
These patients were excluded from the statistical analysis, and
103 patients were evaluated for DFI, semen parameters and
hormone parameters, pre- and post-treatment. Table 1S reports
age, smoking behavior and anthropometric characteristics of the
evaluated patients.
Primary Endpoint: DFI Change From the
Baseline Before and After Treatment
A change from the baseline of the DFI was investigated for
the overall population, as well as for the sub-groups obtained
through stratification of the whole sample on the basis of the
DFI level, age and smoking behavior. The DFI average for
all patients at baseline was 18.41 ± 7.86%. After treatment,
the DFI showed a significant decrease of 35.4% (15.11 ±
5.97%) (p < 0.001) (Table 1). In particular, 69 patients (67%)
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FIGURE 2 | Study flowchart.
TABLE 1 | DFI, semen and hormonal parameters of 103 patients’ baseline and
post-treatment (mean , SD).
Baseline
(visit 0)
Post-treatment
(visit 2)
p-value
DFI (%) 18.41 ± 7.86% 15.11 ± 5.97 <0.001
Seminal volume (mL) 4.31 ± 9.05 3.15 ± 1.31 0.181
Sperm concentration (×106/ml) 60.03 ± 63.89 101.91 ± 122.512 0.001
Total sperm number (×106/ejac) 223.38 ± 284.60 369.28 ± 520.987 <0.001
Sperm motility (%) 20.31 ± 7.32 40.37 ± 17.09 <0.001
Abnormal forms (%) 83.83 ± 14.27 78.43 ± 15.15 0.005
FSH (IU/L) 3.34 ± 1.56 5.74 ± 2.01 <0.001
LH (IU/L) 3.09 ± 1.40 2.84 ± 1.30 0.032
Testosterone (nmol/L) 5.38 ± 6.05 4.99 ± 2.25 0.521
SHBG (nmol/L) 32.02 ± 12.54 32.72 ± 12.32 0.668
AMH (IU/L) 4.01 ± 2.13 5.32 ± 4.05 <0.001
Inhibin B (pg/mL) 160.64 ± 66.75 177.94 ± 77.95 <0.001
Statistically significant differences are in bold.
showed a significant DFI improvement compared to the baseline
(p < 0.001), whereas, 34 patients (33%) showed significant DFI
worsening after treatment (p < 0.001).
Age, smoking behavior, hormone levels and semen parameters
of the sub-groups obtained through stratification of the whole
sample on the basis of the DFI improvement, are shown in Table
2 Sa,b,c. Considering the entire group of patients studied, we
observed that the median value of the DFI at baseline was 17%.
Thus, we divided patients into two sub-groups on the basis of the
median (17%). Forty-eight patients (47%) showed a DFI baseline
below 17% and fifty-five patients (53%) showed a DFI higher
than 17%. The DFI significantly improved of 32.6% compared to
baseline after treatment in the group of patients with a baseline
DFI ≥ 17% (24.18 vs. 16.29% respectively; p < 0.001). On the
contrary, in the sub-group of patients with a baseline DFI< 17%,
a significant increase, from baseline to post-treatment of the DFI
(11.80 vs. 13.76%; p< 0.05) with relative difference of 16.6%, was
observed (Figure 3, Table 3Sa,b,c).
Considering the risk factors of the DNA fragmentation, the
entire group of patients was divided into two separate groups:
smokers (34 patients, 33%) and non-smokers (69 patients; 67%).
The DFI improved in 72% (50/69) of the non-smokers and in
56% (19/34) of the smokers. This result suggests that the FSH
treatment improves the DFI especially in non-smoking patients
(p < 0.001), rather than in the smoking patients (p = 0.309)
(Figure 4).
No significant differences of the DFI improvement were
recorded when dividing patients in relation to their age group
(data not shown).
Finally, patients were divided in quartiles according to the
FSH basal levels distribution (cut-offs: 2.16, 3.13, and 4.27 IU/L).
The DFI improvement after treatment was significant in the
group of patients with FSH between 2.16 and 3.13 IU/L (17.59
± 8.08% vs. 13.66± 5.80%, p= 0.038) and between 3.13 and 4.27
IU/L (19.71 ± 10.30% vs. 15.59 ± 6.91%, p = 0.038). This result
suggests that the FSH efficacy is less evident when the FSH basal
levels were below the first quartile detected in our patients or, on
the other hand, higher than the highest quartile. However, since
we did not investigate any FSH receptor polymorphism, results
should be interpreted accordingly.
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FIGURE 3 | Comparison of the baseline and the post-treatment DFI mean
values, by dividing patients in accordance to the median DFI baseline value of
17% (DFI < 17% – 48 patients and DFI ≥ 17% – 55 patients) (Wilcoxon
signed-rank test). (A) Baseline DFI< 17%, (B) Post treatment DFI < 17%,
(C) Baseline DFI ≥ 17%, (D) Post treatment DFI ≥ 17%. *P < 0.05
***P < 0.001.
FIGURE 4 | Comparison of the baseline and the post-treatment DFI mean
values in smokers (34 patients) and non-smokers (69 patients) (Wilcoxon
signed-rank test). (A) Baseline, non-smokers, (B) post treatment,
non-smokers, (C) baseline, smokers, (D) post treatment, smokers.
***P < 0.001, NS, not significant.
Secondary Efficacy Endpoints: Change
From the Baseline of the Seminal
Parameters
A significant improvement (p < 0.001) of sperm concentration
and total sperm number (in 72% of the patients), total sperm
motility (97%) and morphology (72%) was recorded after
treatment. Semen volume did not change after the FSH treatment
(p= 0.737) (Table 1).
A linear regression analysis was performed using the DFI as
a dependent variable and all seminal parameters as independent
variables. A significant inverse relationship was found, both
at baseline and after treatment, between the DFI and both
sperm concentrations (p = 0.041 and p = 0.001, respectively)
and abnormal forms (p < 0.001 and p = 0.033, respectively).
No differences were seen between the DFI and other seminal
parameters.
For the purpose of analysis, patients were divided into sub-
groups on the basis of the DFI median (17%). This cut-off
was an arbitrary DFI value calculated in accordance with the
DFI distribution in the enrolled population. The comparative
statistical analysis between the DFI < 17% sub-group and the
DFI ≥ 17% sub-group, at baseline, showed a significantly higher
total sperm number, and abnormal forms in the DFI < 17%
sub-group than in the DFI ≥ 17% sub-group. There was no
significant difference found for the sperm motility between the
two groups. We observed improvement in all sperm parameters,
after treatment, in both subgroups (Figure 5, Table 3S).
Change From the Baseline of the Hormonal
Parameters
The FSH, the Inhibin B and the AMH serum levels significantly
increased (p < 0.001) after treatment whereas, the LH
significantly decreased (p = 0.032), even though these values
remained within normal range. No significant differences were
observed in either the testosterone (p = 0.855) or the SHBG
average scores (p= 0.651).
In the risk analysis of the sub-groups, smokers appeared to
be less responsive to treatment, showing weaker improvements
in the AMH and the Inhibin B levels when compared to the
non-smoker sub-groups.
Safety
Overall, 6 Adverse Events (AEs) were registered by clinical
evaluation during the study. Five patients (4.3%) experienced at
least one AE. In five cases, a transient increase of liver enzymes
was recorded and in one other case, an alopecia onset was
reported. No serious AEs occurred and none of the experienced
AEs led to a discontinuation of the study. No severe AEs were
experienced by any of the enrolled patients. The AEs were mild
and transient and all of them were considered unrelated to the
study treatment.
DISCUSSION
The study demonstrates that recombinant FSH administration,
every other day for 3 months, is safe and effective to induce a
significant reduction in sperm DNA damage in infertile men.
This improvement is significantly higher when the baseline DFI
is higher than 17% and the FSH serum levels are between 2.16
and 4.27 IU/L.
The DFI is a well-known marker of sperm quality, and
in literature it has been proposed that DFI higher than 30%
measured with SCSA is to be considered pathological (19).
However, a precise cut-off value may be influenced by different
methods used for DNA damage evaluation and to date it is
still object of debate. We chose the 17% value, the median
of baseline sperm DFI value, as an arbitrary threshold and
should not be considered a clinical cut-off value. Here we found
that the FSH administration improves the DFI levels of more
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FIGURE 5 | Variation in mean semen parameters of 103 patients, baseline and post-treatment, divided in the sub-group with DFI < 17% (48 patients) and DFI ≥ 17%
(55 patients) (Wilcoxon signed-rank test). (A) Baseline DFI < 17%, (B) post treatment DFI < 17%, (C) baseline DFI ≥ 17%, (D) post treatment DFI ≥ 17%. *P < 0.05
***P < 0.001.
than 30% compared to baseline. In fact, our study provides a
demonstration of the beneficial effects of the FSH administration
on spermatogenesis and sperm quality in particular sperm
DNA fragmentation but no data on pregnancy outcome was
considered. In this setting, the DFI remains a surrogate marker
of semen quality and male fertility. The study was designed to
evaluate the male partner in infertile couples, thus we are not
able to conclude whether this increase is enough to improve the
pregnancy rate or the embryo quality.
It is well known that the FSH plays a pivotal role both
in spermatogenesis and in sperm DNA maturation. Moreover,
the FSH is a key regulator of testis function, required for
the establishment of full postnatal development of Sertoli and
germ cells and for the maintenance of spermatogenesis in adult
men (15). FSH plays a synergistic action with testosterone
supporting germ cell survival. For this reason it is plausible
that sperm DNA integrity is also positively affected by this
hormone (15). Considering this background, nowadays, the
recombinant FSH treatment is routinely and empirically used
in clinical practice to improve sperm quality and it represents
the only available therapy in male idiopathic infertility (10).
However, there is no clear evidence of the real beneficial effects
of the FSH administration on routine seminal parameters (11).
Here, we found that the FSH treatment improves total sperm
number, total motility and morphology, suggesting a possible,
measurable effect on spermatogenesis. The DFI and the sperm
quality are strictly related (especially for the concentration
and the morphology aspects), suggesting that the evaluation of
these parameters may help the clinicians in the male infertility
management.
The DFI seems to be a good marker for sperm quality,
even after considering the difficulties and the inter- intra-
assay limits (20). Sperm DNA damage could be due to several
intrinsic and extrinsic factors. Endogenous damage can be
related to protamine deficiency, which leads to the difficulty
in the DNA compaction (21). Other involved factors could
be age, apoptosis interruption and the increase of oxidative
stress (19, 22). On the contrary, known exogenous causes of
DNA damage are heat, chemotherapeutic agents, radiations,
gonadotoxic agents, cigarette smoking, inflammation of the
genital tract, varicocele, and hormone imbalance (23–26). In
fact, DNA damage has been associated with altered FSH
and LH levels (27). Our findings suggest that infertile men
benefit from the FSH administration, in particular, in those
cases with elevated DFI baseline levels (DFI > 17%). This
subgroup seems to be the optimal target for the treatment
cycle with FSH for 3 months. The FSH administration
shows a significant effect that is higher in this subgroups,
suggesting that these men could better respond to the
treatment.
Exogenous agents could influence the sperm DNA integrity
and smoke represents an important influencing factor. Here,
we excluded from the analysis, heavy smokers (more than
20 cigarettes per day), and we demonstrated an unexpectedly
higher mean baseline DFI among the non-smokers, rather
than the smokers in our study. However, non-smoking patients
(particularly in the younger individuals) are more responsive
to the FSH treatment, showing a greater reduction in the
DFI. Consistently, non-smokers with high baseline DFI were
the ones displaying the best response to treatment concerning
the improvements in the sperm DNA damage. These results
confirm the role of exogenous agents and oxidative stress
as a risk factor for the reduction in male fertility, as well
as the predictive role of life-style habits on the response of
the FSH treatment. In particular, this finding introduces new
variables to be considered when choosing which patient should
or should not be treated. However, further properly designed
trials should be taken into consideration in order to evaluate
the precise action of the FSH on testis and seminal glands
and to find out in which spermatogenetic step the FSH acts
in.
Although the vast majority of our patients show a DFI
improvement after FSH administration, 33% of our patients do
not benefit from the therapy. Sub-analyses showed that non-
responders are typically men with FSH basal levels higher than
4.27 IU/L or basal DFI lower than 17%.
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This DFI value is arbitrary andmay not be generalized. In fact,
for TUNEL assay used in this study no clear threshold value exist
to define normal or abnormal sperm quality. Many threshold
values were suggested, ranging from 4 to 35%, and such wide
variability is explained by the absence of standardized laboratory
protocols for TUNEL assay (28). For this reason in our study
sperm DNA integrity analyses were performed in a centralized
Laboratory.
Further specific investigations should be carried out in order
to better clarify the reason for the lack of benefit observed
among these subjects. We could speculate that this finding might
be due to the co-occurrence of other undiagnosed alterations,
which may affect the spermatogenesis and the sperm DNA
condensation. Furthermore, we cannot exclude a correlation
between the response to the FSH treatment and the presence
of the FSH receptor and the FSH-beta chain polymorphisms.
In fact, the occurrence of the FSH receptor polymorphisms
may lead either to an impairment in cell response to therapy
(14, 29) or to variable spermatogenic activity (15, 30). Only
one clinical trial has been reported in the literature showing
that these polymorphisms are able to influence the response to
the FSH administration (12). Thus, the role of genetic asset of
gonadotropins and their receptors should be consider in a fully
study ofmale infertility and to better address the treatment. These
genetic parameters could be useful in the near future to recognize
responders before the treatment.
The study treatment is associated with a general enhancement
of the gonadal function, as described by the improvement of
both hormonal (AMH and Inhibin B) and seminal parameters,
although no changes are found in testosterone and SHBG serum
levels. The AMH increase obtained after FSH administration
confirms the action of this gonadotropin on Sertoli cells. Thus,
we could speculate in favor to the use of this parameter in the
next future to evaluate the efficacy of FSH treatment in male
infertility. In particular, the increase observed in the AMH and in
the Inhibin B levels seems to be further highlighted among non-
smokers, which should confirm the negative impact of oxidative
stress on gonadal functions. However, given the small sample size
of each sub-group, these results are merely indicative and should
be supported by further investigations in larger populations.
Recent studies confirmed that the sperm DNA breaks is a
process of apoptosis triggered by several testicular conditions and
by oxidative stress during the transit in themale genital tract (31).
The clarification of the exact mechanisms leading to the DNA
breaks may help to better design studies aimed at evaluating the
effects of specific drugs for male infertility, duration and regimen.
Finally, although this was a Phase II study, by recruiting and
treating a limited number of patients, preliminary conclusions
concerning the efficacy and safety of the recombinant FSH 150IU
(Gonal-f R© PEN 900 IU) in the treatment of the male partner of
infertile couples can be drawn.
This study shows several limitations, due to the relative low
number of patients treated and the lack of a placebo group
and control group. The latter remains the main challenge in
the setting of both female and male infertility treatment. In
this setting several emotional concerns should be considered
and a high time and cost required during the study. Thus,
so far, it is impossible to design a classical double-blind,
placebo controlled, clinical trial, although it should be the only
scientific method to better address the treatment response. Also,
FSHR polymorphisms that might influence in vivo response to
FSH treatment (such as SNP rs6166), were not investigated.
A stratification for these parameters might have provided
informative results.
Moreover, the study was carried out according to regulations
provided by the AIFA note number 74. However, no clear
demonstration on the correct dose and duration of the treatment
is available at this time. Taking into consideration the duration of
spermatogenesis, further studies should be designed concerning
the different therapeutic approaches to confirm the beneficial role
of FSH in male infertility.
CONCLUSION
This study provided encouraging, effective results and an
adequate level of confidence concerning safety, suggesting
to proceed to Phase III ad hoc studies in larger populations,
aimed at exploring the FSH potential efficacy in infertile
men. These trials may be useful to evaluate if the male
treatment could improve major outcomes, such as embryo
quality and pregnancy rate during assisted reproductive
techniques.
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